Pharmacogenetics and Genomics

Papers
(The TQCC of Pharmacogenetics and Genomics is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
MEG3 in hematologic malignancies: from the role of disease biomarker to therapeutic target15
Establishing national reference materials for genetic testing of cytochrome P45012
Luteal phase stimulation in double ovarian stimulation cycles is not affected by the follicle-stimulating hormone (FSH) receptor genotype: double ovarian stimulation is beneficial independently of the11
Novel variant in Nudix hydrolase 15 gene influences 6-mercaptopurine toxicity in childhood acute lymphoblastic leukemia patients11
Effect of CYP2C19 genetic variants on bleeding and major adverse cardiovascular events in a cohort of Arab patients undergoing percutaneous coronary intervention and stent implantation11
The prevalence of pharmacogenetic testing in the United States10
The impact of genetic variations in FPGS, MTHFR, and ATIC on methotrexate response among pediatric patients with acute lymphoblastic leukemia9
Impact of CYP3A5 genotype on de-novo LCP tacrolimus dosing and monitoring in kidney transplantation9
Common dihydropyrimidinase (DPYS) genetic variations do not predict fluoropyrimidine-related chemotherapy toxicity in a Canadian cohort8
Pharmacogenetics of tuberculosis treatment toxicity and effectiveness in a large Brazilian cohort7
Effect of CYP2D6 genetic variation on patient-reported symptom improvement and side effects among children and adolescents treated with amphetamines7
Unraveling the genetic link: an umbrella review on HLA-B*15:02 and antiepileptic drug-induced Stevens–Johnson syndrome/toxic epidermal necrolysis7
Annual Scientific Meeting of the Pharmacogenomics Global Research Network (PGRN) June 12-13, 2023 Memphis, TN, USA7
Associations of CYP2C19 and F2R genetic polymorphisms with platelet reactivity in Chinese ischemic stroke patients receiving clopidogrel therapy6
PharmGKB summary: disulfiram pathway6
Integrating pharmacogenetics in sport medicine: enhancing treatment precision and preventing unintentional doping violation5
Effects of CYP3A5*3 genetic polymorphisms on the pharmacokinetics of perampanel in Chinese pediatric patients with epilepsy5
Genome-wide DNA methylation profile of peripheral blood lymphocytes from subjects with nonsteroidal anti-inflammatory drug-induced respiratory diseases5
Updating probability of pathogenicity for RYR1 and CACNA1S exon variants in individuals without malignant hyperthermia after exposure to triggering anesthetics5
Pharmacogenomic allele coverage of genome-wide genotyping arrays: a comparative analysis5
N-acetyltransferase 2 haplotype modifies risks for both dyslipidemia and urinary bladder cancer5
Updated analysis of the pharmacogenomics of pediatric bronchodilator response4
HDL-C and creatinine levels at 1 month are associated with patient 12-month survival rate after kidney transplantation4
The c.415C>T polymorphism in NUDT15 is more frequent than the polymorphisms in TPMT in Chilean patients who use thiopurine drugs4
Genetic polymorphisms effect on cyclophosphamide’s tolerability and clinical efficacy in Egyptian patients with lupus nephritis4
Anesthesia providers as stakeholders to adoption of pharmacogenomic information in perioperative care4
Mouse nerve growth factor suppresses neuronal apoptosis in valproic acid-induced autism spectrum disorder rats by regulating the phosphoinositide-3-kinase/serine/threonine kinase signaling pathway4
Identification of potential druggable targets of cell cycle with small-molecule inhibitors in oral squamous cell carcinoma3
Associations of ADH1B and ALDH2 genotypes and alcohol flushing with drinking history, withdrawal symptoms, and ICD-10 criteria in Japanese alcohol-dependent men3
MiRNA-139-3p inhibits malignant progression in urothelial carcinoma of the bladder via targeting KIF18B and inactivating Wnt/beta-catenin pathway3
Two polymorphic gene loci associated with treprostinil dose in pulmonary arterial hypertension3
Impact of organic anion transporting polypeptide, P-glycoprotein, and breast cancer resistance protein transporters on observed tamoxifen and endoxifen concentration and adverse effects3
Pharmacogenetics of weight gain following switch from efavirenz- to integrase inhibitor-containing regimens3
0.10584187507629